David Darling has a dig at DHB delays

David Darling has a dig at DHB delays
David Darling: Disappointed with slow adoption (Image: Supplied)
Brent Melville
Pacific Edge’s cancer diagnostic products have made headway into the US healthcare sector over the past several years, but many New Zealand patients continue to be shut out by the bureaucracy of local DHBs, the company says.Last June, the NZX-listed firm announced giant US healthcare group Kaiser Permanente had approved its Cxbladder products for use by urologists to monitor patients for bladder cancer. A month later it announced Cxbladder tests will be covered by the Centers for Medicare and Medicaid Services (CMS) across the US mar...

More Markets

'Serious compliance breaches' in NZ sharemarket
Markets

'Serious compliance breaches' in NZ sharemarket

Seven matters were referred to the NZ Markets Disciplinary Tribunal last year.

Which NZX firms lost or gained NZ Super Fund investment
Markets

Which NZX firms lost or gained NZ Super Fund investment

The fund is an active investor in NZ. Here are the firms it likes, and those it dumped.

Gas fears weigh on Genesis, push up power prices
Markets

Gas fears weigh on Genesis, push up power prices

Worries about gas supply hit more than share prices.

Analysts sour on Air New Zealand
Markets

Analysts sour on Air New Zealand

Analysts are more downbeat after a downgrade.